Cover Image
市場調查報告書

全球睪丸癌治療藥市場

Global Testicular Cancer Drugs Market 2014-2018

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 294980
出版日期 內容資訊 英文 52 Pages
訂單完成後即時交付
價格
Back to Top
全球睪丸癌治療藥市場 Global Testicular Cancer Drugs Market 2014-2018
出版日期: 2014年01月17日 內容資訊: 英文 52 Pages
簡介

全球睪丸癌治療藥市場,預計以睪丸癌的發病率增加和聯合治療的出現為背景,從2013年到2018年以年複合成長率4.02%增長。可是,替代療法的存在可能成為阻礙市場的要素。

本報告以南北美洲、亞太地區、歐洲、中東、非洲地區為對象,提供全球睪丸癌治療藥市場情勢分析、未來預測、成長要素和課題彙整、主要的供應商的資訊,為您概述為以下內容。

第1章 摘要整理

第2章 簡稱集

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 簡介

第6章 市場形勢

  • 市場概要
  • 市場規模及預測
  • 波特的五力分析

第7章 各類型:睪丸癌

  • 精原細胞瘤
  • 非精原細胞瘤(精原細胞瘤)

第8章 各階段:睪丸癌

第9章 治療的種類

  • 手術
  • 放射治療
  • 化療

第10章 臨床試驗趨勢的摘錄

第11章 各地理市場區隔

  • 各地理市場區隔

第12章 購買標準

第13章 發病率和得病率

第14章 市場成長要素

第15章 成長要素與其影響

第16章 市場課題

第17章 成長要素與課題的影響

第18章 市場趨勢

第19章 市場趨勢與其影響

第20章 業者情勢

  • 競爭模式
  • 其他卓越的供應商

第21章 主要供應商分析

  • Bristol-Myers Squibb Co.
  • Hospira Inc.
  • Teva Pharmaceutical Industries Ltd.
  • ZIOPHARM Oncology Inc.

第22章 相關報告

圖表

目錄
Product Code: IRTNTR3215

TechNavio's analysts forecast the Global Testicular Cancer Drugs market to grow at a CAGR of 4.02 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing incidence of testicular cancer. The Global Testicular Cancer Drugs market has also been witnessing the emergence of combination therapies for the treatment of testicular cancer. However, the presence of alternative testicular cancer treatments could pose a challenge to the growth of this market.

TechNavio's report, the Global Testicular Cancer Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market market in the Americas, and the EMEA and APAC regions; it also covers the Global Testicular Cancer Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors dominating this space include Bristol-Myers Squibb Co., Hospira Inc., Teva Pharmaceutical Industries Ltd., and ZIOPHARM Oncology Inc.

Other vendors mentioned in the report are Baxter International Inc., Fresenius Kabi Pharmaceuticals Holding Inc., and Mylan Pharmaceutical Inc.

Key questions answered in this report:

  • What will the market size be in 2016/2018 and what will be the growth rate?
  • What are key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by key vendors?
  • What are the strengths and weaknesses of each of these key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details provided within the report.

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. Five Forces Analysis

07. Testicular Cancer by Type

  • 07.1.1. Seminoma
  • 07.1.2. Non-seminoma

08. Testicular Cancer Disease by Stages

  • 08.1.1. Stage 0
  • 08.1.2. Stage I
  • 08.1.3. Stage II
  • 08.1.4. Stage III

09. Treatment Options

  • 09.1. Surgery
  • 09.2. Radiation Therapy
  • 09.3. Chemotherapy

10. Clinical Trial Snapshot

11. Geographical Segmentation

  • 11.1. Global Testicular Cancer Drugs Market by Geographical Segmentation

12. Buying Criteria

13. Rate of Incidence and Prevalence

14. Market Growth Drivers

15. Drivers and their Impact

16. Market Challenges

17. Impact of Drivers and Challenges

18. Market Trends

19. Trends and their Impact

20. Vendor Landscape

  • 20.1. Competitive Scenario
    • 20.1.1. Key News
    • 20.1.2. Acquisitions
  • 20.2. Other Prominent Vendors

21. Key Vendor Analysis

  • 21.1. Bristol-Myers Squibb Co.
    • 21.1.1. Business Overview
    • 21.1.2. Key Information
    • 21.1.3. SWOT Analysis
  • 21.2. Hospira Inc.
    • 21.2.1. Business Overview
    • 21.2.2. Business Segmentation
    • 21.2.3. Key Information
    • 21.2.4. SWOT Analysis
  • 21.3. Teva Pharmaceutical Industries Ltd.
    • 21.3.1. Business Overview
    • 21.3.2. Business Segmentation
    • 21.3.3. Key Information
    • 21.3.4. SWOT Analysis
  • 21.4. ZIOPHARM Oncology Inc.
    • 21.4.1. Business Overview
    • 21.4.2. Key Information
    • 21.4.3. SWOT Analysis

22. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Testicular Cancer Drugs market 2013-2018 (US$ million)
  • Exhibit 3: Testicular Cancer Segmentation by Type
  • Exhibit 4: Global Testicular Cancer Drugs Market by Geographical Segmentation 2013 (percent)
  • Exhibit 5: Business Segmentation of Hospira Inc.
  • Exhibit 6: Business Segmentation of Teva Pharmaceutical Industries Ltd.
Back to Top